The projects of this laboratory aim to provide new chemical genetic tools to define, perturb and manipulate essential functions of protein methyltransferases. Another focus in this laboratory is to design and synthesize tight-binding inhibitors as anti-cancer drug candidates by blocking these protein-modifying activities. Researchers in the field of chemistry, biology and biochemistry work together closely to synthesize novel chemical reagents, elucidate illness-causing mechanisms at molecular level and develop potential treatments for human diseases.
Minkui Luo, PhD
Research FocusChemist Minkui Luo develops chemical tools to elucidate protein-posttranslational modification and designs inhibitors for cancer therapies.
- PhD, Princeton University
- Ian R. Bothwell and Minkui Luo, “Large-scale, Protection-free Synthesis of Se-Adenosyl-L-selenomethionine Analogues and Their Application as Cofactor Surrogates of Methyltransferases”, Org. Lett. 2014, 16, 3056-3059. This paper was featured by Today’s Science Sparks at MSKCC.
- Han Guo, Rui Wang, Weihong Zheng, Yuling Chen, Gil Blum, Haiteng Deng and Minkui Luo, “Profiling Substrates of Protein Arginine N-Methyltransferase 3 with S-Adenosyl-L-methionine Analogues”, ACS Chemical Biology, 2014, 9, 476-484. PMCID:PMC3944066
- Basil O'Connor Starter Scholar, March of Dimes Birth Defects Foundation (2011)
- Director’s New Innovator Award, National Institutes of Health (2010)
- Alfred W. Bressler Scholar, Alfred W. Bressler Scholars Endowment Fund (2010)
- V Scholar Award, V Foundation for Cancer Research (2009)
- Outstanding Postdoctoral Research Prize, Albert Einstein College of Medicine (2007)